Is CERS or XRAY more profitable?

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% DENTSPLY SIRONA -14.99% 20.84% 5.32%

Does the media prefer CERS or XRAY?

In the previous week, DENTSPLY SIRONA had 13 more articles in the media than Cerus. MarketBeat recorded 17 mentions for DENTSPLY SIRONA and 4 mentions for Cerus. Cerus' average media sentiment score of 1.34 beat DENTSPLY SIRONA's score of 0.07 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DENTSPLY SIRONA 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVNS or CERS?

Cerus has a consensus target price of $5.25, suggesting a potential upside of 103.49%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cerus 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is AVNS or CERS more profitable?

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Avanos Medical -10.39% 5.39% 3.97% Cerus -3.06% -10.19% -3.14%

Does the media refer more to AVNS or CERS?

In the previous week, Avanos Medical had 1 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Avanos Medical and 4 mentions for Cerus. Avanos Medical's average media sentiment score of 1.78 beat Cerus' score of 1.34 indicating that Avanos Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avanos Medical 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CERS or QDEL more profitable?

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% QuidelOrtho -39.20% 4.88% 1.63%

Does the media refer more to CERS or QDEL?

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 5 mentions for QuidelOrtho and 4 mentions for Cerus. QuidelOrtho's average media sentiment score of 1.49 beat Cerus' score of 1.34 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CERS or SMTI?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $221.55M 2.35 -$15.63M -$0.03 N/A Sanara MedTech $103.12M 3.09 -$37.56M -$3.59 N/A

Is CERS or SMTI more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Sanara MedTech -29.15% 29.72% 2.84%

Does the media favor CERS or SMTI?

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Sanara MedTech. Cerus' average media sentiment score of 1.34 beat Sanara MedTech's score of 0.51 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, EMBC or CERS?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.02B 0.32 $95.40M $1.48 3.84 Cerus $221.55M 2.35 -$15.63M -$0.03 N/A

Is EMBC or CERS more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% Cerus -3.06% -10.19% -3.14%

Does the media prefer EMBC or CERS?

In the previous week, Cerus had 1 more articles in the media than Embecta. MarketBeat recorded 4 mentions for Cerus and 3 mentions for Embecta. Cerus' average media sentiment score of 1.34 beat Embecta's score of 0.22 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cerus (CERS) Competitors

$2.58 -0.02 (-0.77%)

As of 02:40 PM Eastern

Compare

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

Should you buy Cerus stock or one of its competitors? Cerus's main competitors and comparable companies include DENTSPLY SIRONA (XRAY), Avanos Medical (AVNS), QuidelOrtho (QDEL), Sanara MedTech (SMTI), and Embecta (EMBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Cerus compare to DENTSPLY SIRONA?

Cerus (NASDAQ:CERS) and DENTSPLY SIRONA (NASDAQ:XRAY) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

In the previous week, DENTSPLY SIRONA had 13 more articles in the media than Cerus. MarketBeat recorded 17 mentions for DENTSPLY SIRONA and 4 mentions for Cerus. Cerus' average media sentiment score of 1.34 beat DENTSPLY SIRONA's score of 0.07 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DENTSPLY SIRONA	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

78.4% of Cerus shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cerus currently has a consensus target price of $5.25, indicating a potential upside of 103.49%. DENTSPLY SIRONA has a consensus target price of $13.54, indicating a potential upside of 19.28%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than DENTSPLY SIRONA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
DENTSPLY SIRONA	3 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cerus has higher earnings, but lower revenue than DENTSPLY SIRONA. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A
DENTSPLY SIRONA	$3.64B	0.62	-$598M	-$2.75	N/A

Cerus has a net margin of -3.06% compared to DENTSPLY SIRONA's net margin of -14.99%. DENTSPLY SIRONA's return on equity of 20.84% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
DENTSPLY SIRONA	-14.99%	20.84%	5.32%

Summary

Cerus beats DENTSPLY SIRONA on 9 of the 15 factors compared between the two stocks.

How does Cerus compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Cerus has lower revenue, but higher earnings than Avanos Medical. Cerus is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A

Cerus has a net margin of -3.06% compared to Avanos Medical's net margin of -10.39%. Avanos Medical's return on equity of 5.39% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Cerus	-3.06%	-10.19%	-3.14%

Avanos Medical has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Cerus has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

In the previous week, Avanos Medical had 1 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Avanos Medical and 4 mentions for Cerus. Avanos Medical's average media sentiment score of 1.78 beat Cerus' score of 1.34 indicating that Avanos Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avanos Medical	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus has a consensus target price of $5.25, suggesting a potential upside of 103.49%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 2.3% of Avanos Medical shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cerus beats Avanos Medical on 9 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Cerus has a net margin of -3.06% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
QuidelOrtho	-39.20%	4.88%	1.63%

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A
QuidelOrtho	$2.67B	0.35	-$1.13B	-$15.41	N/A

Cerus has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, QuidelOrtho had 1 more articles in the media than Cerus. MarketBeat recorded 5 mentions for QuidelOrtho and 4 mentions for Cerus. QuidelOrtho's average media sentiment score of 1.49 beat Cerus' score of 1.34 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of Cerus shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cerus presently has a consensus target price of $5.25, suggesting a potential upside of 103.49%. QuidelOrtho has a consensus target price of $13.63, suggesting a potential downside of 1.27%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Cerus beats QuidelOrtho on 9 of the 16 factors compared between the two stocks.

How does Cerus compare to Sanara MedTech?

Cerus (NASDAQ:CERS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Cerus had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Cerus and 2 mentions for Sanara MedTech. Cerus' average media sentiment score of 1.34 beat Sanara MedTech's score of 0.51 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus presently has a consensus price target of $5.25, indicating a potential upside of 103.49%. Sanara MedTech has a consensus price target of $35.00, indicating a potential upside of 0.92%. Given Cerus' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Sanara MedTech	-29.15%	29.72%	2.84%

78.4% of Cerus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 5.3% of Cerus shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cerus has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A
Sanara MedTech	$103.12M	3.09	-$37.56M	-$3.59	N/A

Summary

Cerus beats Sanara MedTech on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to Embecta?

Embecta (NASDAQ:EMBC) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Embecta presently has a consensus price target of $11.00, indicating a potential upside of 93.32%. Cerus has a consensus price target of $5.25, indicating a potential upside of 103.49%. Given Cerus' stronger consensus rating and higher possible upside, analysts plainly believe Cerus is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
Cerus	-3.06%	-10.19%	-3.14%

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.02B	0.32	$95.40M	$1.48	3.84
Cerus	$221.55M	2.35	-$15.63M	-$0.03	N/A

In the previous week, Cerus had 1 more articles in the media than Embecta. MarketBeat recorded 4 mentions for Cerus and 3 mentions for Embecta. Cerus' average media sentiment score of 1.34 beat Embecta's score of 0.22 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Cerus has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

93.8% of Embecta shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 1.3% of Embecta shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cerus beats Embecta on 9 of the 16 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$519.93M	$5.70B	$7.26B	$12.91B
Dividend Yield	N/A	1.75%	2.53%	8.56%
P/E Ratio	-86.00	25.90	273.83	25.42
Price / Sales	2.35	84.32	676.21	123.96
Price / Cash	N/A	33.05	76.98	52.08
Price / Book	7.37	6.06	12.89	6.17
Net Income	-$15.63M	$150.03M	$3.48B	$349.24M
7 Day Performance	-5.15%	-1.25%	-0.36%	-1.42%
1 Month Performance	20.00%	3.33%	6.49%	2.53%
1 Year Performance	96.95%	7.45%	25.06%	15.84%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	2.325 of 5 stars	$2.58 -0.8%	$5.25 +103.5%	+104.7%	$519.93M	$221.55M	N/A	290	Positive News
XRAY DENTSPLY SIRONA	4.476 of 5 stars	$10.72 -1.6%	$13.54 +26.3%	-18.2%	$2.14B	$3.64B	N/A	14,000
AVNS Avanos Medical	0.5828 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287	Positive News
QDEL QuidelOrtho	1.8117 of 5 stars	$14.68 +1.3%	$13.63 -7.2%	-50.6%	$1.01B	$2.67B	N/A	6,500
SMTI Sanara MedTech	1.235 of 5 stars	$34.40 +0.1%	$35.00 +1.7%	+0.5%	$316.14M	$103.12M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

How does Cerus compare to DENTSPLY SIRONA?

Summary

How does Cerus compare to Avanos Medical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to Sanara MedTech?

Summary

How does Cerus compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. XRAY, AVNS, QDEL, SMTI, and EMBC

How does Cerus compare to DENTSPLY SIRONA?

Does the media prefer CERS or XRAY?

Which has more risk and volatility, CERS or XRAY?

Do insiders and institutionals have more ownership in CERS or XRAY?

Do analysts prefer CERS or XRAY?

Which has better valuation & earnings, CERS or XRAY?

Is CERS or XRAY more profitable?

Summary

How does Cerus compare to Avanos Medical?

Which has better earnings & valuation, AVNS or CERS?

Is AVNS or CERS more profitable?

Which has more risk & volatility, AVNS or CERS?

Does the media refer more to AVNS or CERS?

Do analysts recommend AVNS or CERS?

Do insiders and institutionals hold more shares of AVNS or CERS?

Summary

How does Cerus compare to QuidelOrtho?

Is CERS or QDEL more profitable?

Which has preferable valuation & earnings, CERS or QDEL?

Which has more volatility & risk, CERS or QDEL?

Does the media refer more to CERS or QDEL?

Do institutionals and insiders believe in CERS or QDEL?

Do analysts prefer CERS or QDEL?

Summary

How does Cerus compare to Sanara MedTech?

Does the media favor CERS or SMTI?

Do analysts prefer CERS or SMTI?

Is CERS or SMTI more profitable?

Do insiders & institutionals believe in CERS or SMTI?

Which has more volatility & risk, CERS or SMTI?

Which has stronger earnings & valuation, CERS or SMTI?

Summary

How does Cerus compare to Embecta?

Do analysts prefer EMBC or CERS?

Is EMBC or CERS more profitable?

Which has stronger valuation and earnings, EMBC or CERS?

Does the media prefer EMBC or CERS?

Which has more volatility and risk, EMBC or CERS?

Do insiders and institutionals have more ownership in EMBC or CERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools